Graphite Bio, Inc. logo

Graphite Bio, Inc.

NASDAQ:GRPH

Overview | Financials
Company Name Graphite Bio, Inc.
Symbol GRPH
Currency USD
Price 3.18
Market Cap 185,193,342
Dividend Yield 64.78%
52-week-range 3.05 - 29.82
Industry Biotechnology
Sector Healthcare
CEO Ms. Kimberlee Cobleigh Drapkin CPA, CPA
Website https://www.graphitebio.com

An error occurred while fetching data.

About Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for

Related Stocks

Pieris Pharmaceuticals, Inc. logo

Pieris Pharmaceuticals, Inc.

PIRS

17.04 USD

Genenta Science S.p.A. logo

Genenta Science S.p.A.

GNTA

4.135 USD

Apyx Medical Corporation logo

Apyx Medical Corporation

APYX

1.3 USD

ImmunoPrecise Antibodies Ltd. logo

ImmunoPrecise Antibodies Ltd.

IPA

0.67 USD

ORIC Pharmaceuticals, Inc. logo

ORIC Pharmaceuticals, Inc.

ORIC

9.65 USD

Gritstone bio, Inc. logo

Gritstone bio, Inc.

GRTS

0.467 USD

CorMedix Inc. logo

CorMedix Inc.

CRMD

5.76 USD

Financials

Numbers are in millions USD

Numbers are in millions USD